Overview

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
- To evaluate if weekly psychological follow-up make opioid dependent patients in MMT able to accomplish 14 weeks treatment with Peginterferon alfa-2a (PEG-INF) and ribavirin to the same extent than non-opioid dependents. - To determine the efficacy of this anti-HCV treatment
Phase:
Phase 3
Details
Lead Sponsor:
Sorlandet Hospital HF
Treatments:
Interferons
Methadone
Ribavirin